The noradrenergic agent reboxetine plus antimuscarinic hyoscine butylbromide reduces sleep apnoea severity: A double‐blind, placebo‐controlled, randomised crossover trial

2021 ◽  
Author(s):  
Richard Lim ◽  
Ludovico Messineo ◽  
Ronald R. Grunstein ◽  
Jayne C. Carberry ◽  
Danny J. Eckert
Keyword(s):  
Crossover Trial ◽  
Sleep Apnoea ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Hyoscine Butylbromide

scholarly journals Chronotherapy for hypertension in obstructive sleep apnoea (CHOSA): a randomised, double-blind, placebo-controlled crossover trial

Thorax ◽  
2016 ◽  
Vol 72 (6) ◽  
pp. 550-558 ◽  
Author(s):  
Yasmina Serinel ◽  
Brendon J Yee ◽  
Ronald R Grunstein ◽  
Keith H Wong ◽  
Peter A Cistulli ◽  
...  
Keyword(s):  
Obstructive Sleep Apnoea ◽  
Crossover Trial ◽  
Sleep Apnoea ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Obstructive Sleep

scholarly journals Acute effects of dapagliflozin on renal oxygenation and perfusion in type 1 diabetes with albuminuria: A randomised, double-blind, placebo-controlled crossover trial

2021 ◽  
pp. 100895
Author(s):  
Jens Christian Laursen ◽  
Niels Søndergaard-Heinrich ◽  
Joana Mendes Lopes de Melo ◽  
Bryan Haddock ◽  
Ida Kirstine Bull Rasmussen ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Crossover Trial ◽  
Acute Effects ◽  
Double Blind ◽  
Double Blind Placebo

scholarly journals Desipramine improves upper airway collapsibility and reduces OSA severity in patients with minimal muscle compensation

2016 ◽  
Vol 48 (5) ◽  
pp. 1340-1350 ◽  
Author(s):  
Luigi Taranto-Montemurro ◽  
Scott A. Sands ◽  
Bradley A. Edwards ◽  
Ali Azarbarzin ◽  
Melania Marques ◽  
...  
Keyword(s):  
Crossover Trial ◽  
Positive Airway Pressure ◽  
Upper Airway ◽  
Sleep Apnoea ◽  
Double Blind ◽  
Healthy Humans ◽  
Dilator Muscle ◽  
Obstructive Sleep ◽  
Airway Collapsibility ◽  
Upper Airway Collapsibility

We recently demonstrated that desipramine reduces the sleep-related loss of upper airway dilator muscle activity and reduces pharyngeal collapsibility in healthy humans without obstructive sleep apnoea (OSA). The aim of the present physiological study was to determine the effects of desipramine on upper airway collapsibility and apnoea–hypopnea index (AHI) in OSA patients.A placebo-controlled, double-blind, randomised crossover trial in 14 OSA patients was performed. Participants received treatment or placebo in randomised order before sleep. Pharyngeal collapsibility (critical collapsing pressure of the upper airway (Pcrit)) and ventilation under both passive (V′0,passive) and active (V′0,active) upper airway muscle conditions were evaluated with continuous positive airway pressure (CPAP) manipulation. AHI was quantified off CPAP.Desipramine reduced activePcrit(median (interquartile range) −5.2 (4.3) cmH2O on desipramineversus−1.9 (2.7) cmH2O on placebo; p=0.049) but not passivePcrit(−2.2 (3.4)versus−0.7 (2.1) cmH2O; p=0.135). A greater reduction in AHI occurred in those with minimal muscle compensation (defined asV′0,active−V′0,passive) on placebo (r=0.71, p=0.009). The reduction in AHI was driven by the improvement in muscle compensation (r=0.72, p=0.009).In OSA patients, noradrenergic stimulation with desipramine improves pharyngeal collapsibility and may be an effective treatment in patients with minimal upper airway muscle compensation.

scholarly journals A Double-Blind Placebo-Controlled Crossover Trial of Intravenous Magnesium Sulfate for Foscarnet-Induced Ionized Hypocalcemia and Hypomagnesemia in Patients with AIDS and Cytomegalovirus Infection

2000 ◽  
Vol 44 (8) ◽  
pp. 2143-2148 ◽  
Author(s):  
Mark M. Huycke ◽  
M. Tarek Naguib ◽  
Mathias M. Stroemmel ◽  
Kenneth Blick ◽  
Katherine Monti ◽  
...  
Keyword(s):  
Crossover Trial ◽  
Serum Magnesium ◽  
Antiviral Agent ◽  
Chronically Ill ◽  
Normal Serum ◽  
Common Side Effect ◽  
Cytomegalovirus Disease ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Intravenous Magnesium

ABSTRACT Foscarnet (trisodium phosphonoformate hexahydrate) is an antiviral agent used to treat cytomegalovirus disease in immunocompromised patients. One common side effect is acute ionized hypocalcemia and hypomagnesemia following intravenous administration. Foscarnet-induced ionized hypomagnesemia might contribute to ionized hypocalcemia by impairing excretion of preformed parathyroid hormone (PTH) or by producing target organ resistance. Prevention of ionized hypomagnesemia following foscarnet administration could blunt the development of ionized hypocalcemia. To determine whether intravenous magnesium ameliorates the decline in ionized calcium and/or magnesium following foscarnet infusions, MgSO4 at doses of 1, 2, and 3 g was administered in a double-blind, placebo-controlled, randomized, crossover trial to 12 patients with AIDS and cytomegalovirus disease. Overall, increasing doses of MgSO4 reduced or eliminated foscarnet-induced acute ionized hypomagnesemia. Supplementation, however, had no discernible effect on foscarnet-induced ionized hypocalcemia despite significant increases in serum PTH levels. No dose-related, clinically significant adverse events were found, suggesting that intravenous supplementation with up to 3 g of MgSO4 was safe in this chronically ill population. Since parenteral MgSO4 did not alter foscarnet-induced ionized hypocalcemia or symptoms associated with foscarnet, routine intravenous supplementation for patients with normal serum magnesium levels is not recommended during treatment with foscarnet.

Sign in / Sign up

Export Citation Format

Share Document